Titrate to achieve optimal clinical improvement1

Evaluating parameters, such as hyperglycemia/type 2 diabetes, glucose-control medications, weight, and psychiatric symptoms, can provide an early assessment of response (within 6 weeks) and help guide early dose titration.1

Monitor blood potassium, blood sugar, and blood pressure consistently. Measurement of cortisol levels is not an effective measure of treatment response.1

Up arrow icon.

Increase Korlym dose if the patient has not yet achieved sufficient clinical improvement

Right arrow icon.

Maintain Korlym dose if the patient has achieved sufficient clinical improvement

Down arrow icon.

Decrease Korlym dose if the patient is unable to tolerate the current dose

Stop icon.

Stop Korlym dose if the patient experiences a serious adverse effect

Decisions about dose increases should be based on clinical assessment of tolerability and the degree of improvement in Cushing syndrome manifestations.1

Because of the variability in clinical presentation and variability of response in the open-label trial, it is uncertain whether the change in body weight or psychiatric symptoms could be ascribed to the effects of Korlym.1

Learn more about optimizing Korlym with this dosing card

  1. Korlym Prescribing Information. Corcept Therapeutics, Inc; 2019.